Similar to our finding, systemic Treg expansion in transgenic AD mice models, including low dose IL-2 administration, modified neuroinflammation and enhanced neuroprotection against AD pathology [32, 37, 38]. This evidence concerns the gene IL2 and Alzheimer disease.